Navidea Biopharmaceuticals Inc

Type: Company
Name: Navidea Biopharmaceuticals Inc
First reported Jul 09 2014 - Updated Jul 09 2014 - 1 reports

Navidea Biopharmaceuticals' (NAVB) CEO Michael Goldberg on Investor Briefing on Sentinel Lymph Node Biopsy in Head & Neck Cancers (Transcript)

Navidea Biopharmaceuticals, Inc. ( NAVB )Related Biotechnology, Pharmaceutical and Healthcare NewsInvestor Briefing on Sentinel Lymph Node Biopsy in Head & Neck Cancers Conference CallJuly 8, 2014, 08:00 AM ETExecutivesStephen Lai - Associate Professor, ... [Published BioPortfolio - Jul 09 2014]
First reported Jul 02 2014 - Updated Jul 02 2014 - 3 reports

Navidea to Webcast Investor Briefing on Sentinel Lymph Node Biopsy in Head & Neck Cancers July 8, 2014

DUBLIN, Ohio--(EON: Enhanced Online News)--Navidea will host a webcast of an investor briefing to discuss the role of sentinel lymph node biopsy in head and neck cancers on Tuesday, July 8, 2014 with a guest speaker, Dr. Stephen Lai. ... [Published EON Science - Jul 02 2014]
First reported Jun 27 2014 - Updated Jun 27 2014 - 2 reports

Navidea announces positive results from Phase III solid tumor analyses

Navidea Biopharmaceuticals, Inc., a provider of diagnostic radiopharmaceuticals, has announced positive results from combined analyses of Phase III clinical trials that evaluated Lymphoseek efficacy in lymphatic mapping for identifying pathology-positive ... [Published Individual.com - Jun 27 2014]
First reported Jun 18 2014 - Updated Jun 19 2014 - 3 reports

Navidea Gets U.S. FDA Approval for sNDA for Expanded Use of Lymphoseek Injection

Navidea Biopharmaceuticals said that the U.S. Food and Drug Administration (FDA) has approved the Supplemental New Drug Application (sNDA) for the expanded use of Lymphoseek (technetium Tc 99m tilmanocept) Injection indicated for guiding sentinel lymph ... [Published Individual.com - Jun 19 2014]
First reported Jun 17 2014 - Updated Jun 18 2014 - 1 reports

Navidea Biopharmaceuticals to Present at the 9th Annual JMP Securities Healthcare Conference

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea to present at JMP Securities Healthcare Conference on June 24, 2014 at 2 p.m. EDT. ... [Published Business Wire Health News - Jun 17 2014]
First reported Jun 17 2014 - Updated Jun 17 2014 - 2 reports

Navidea Biopharmaceuticals to Present at the 9th Annual JMP Securit...

Navidea Biopharmaceuticals to Present at the 9th Annual JMP Securities Healthcare ConferenceJun. 17, 2014 Business EditorsDUBLIN, Ohio--(BUSINESS WIRE)--Jun. 17, 2014--Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused ... [Published Finwin - Jun 17 2014]
First reported Jun 16 2014 - Updated Jun 16 2014 - 3 reports

U.S. FDA Approves Navidea Biopharmaceuticals' Lymphoseek® (technetium Tc 99m tilmanocept) Injection for Expanded Use

- Lymphoseek is first and only FDA-approved sentinel lymph node biopsy agent for use in head and neck cancer patients with oral cavity carcinoma -- Lymphoseek now available for multiple patient populations using existing reimbursement codes -Story Continues ... [Published Dotmed - Jun 16 2014]
First reported Jun 16 2014 - Updated Jun 16 2014 - 1 reports

FDA approves Navidea's Lymphoseek for expanded use in head and neck cancer patients

The US Food and Drug Administration (FDA) has approved Navidea Biopharmaceuticals' Supplemental New Drug Application (sNDA) for the expanded use of Lymphoseek (technetium Tc 99m tilmanocept) Injection indicated for guiding sentinel lymph node (SLN) biopsy ... [Published PBR - News - Jun 16 2014]
First reported Jun 13 2014 - Updated Jun 14 2014 - 2 reports

Biotech Stock Mailbag: Vanda, Navidea, Provectus

If your browser does not automatically forward you to http://business-news.thestreet.com/philly/story/biotech-stock-mailbag-vanda-navidea-provectus/12741934, please click here. ... [Published Philly.com - Jun 13 2014]
First reported Jun 13 2014 - Updated Jun 14 2014 - 16 reports

FDA Approves New Indication For Navidea's Lymphatic Mapping Agent

Navidea Biopharmaceuticals Inc. (NAVB: Quote) has won FDA approval for the expanded use of its lymphatic mapping agent - Lymphoseek - for guiding sentinel lymph node (SLN) biopsy in head and neck cancer patients with squamous cell carcinoma of the oral ... [Published RTTNews.com - Jun 14 2014]
First reported Jun 13 2014 - Updated Jun 13 2014 - 1 reports

Healthcare Review: Arrowhead Research, Navidea Biopharmaceuticals, Cellectar Biosciences, BrainStorm Cell Therapeutics, OncoMed

U.S. stocks rose on Friday, boosted by bullish news from the tech sector, though major indexes remained on track to snap a multi-week string of weekly gains.Despite the day's rise, investors remained cautious about ongoing violence in Iraq, which has ... [Published BioMedReports - Jun 13 2014]
First reported Jun 11 2014 - Updated Jun 11 2014 - 6 reports

Navidea touts Lymphoseek phase III trial

-- Navidea Biopharmaceuticals is highlighting results from a phase III clinical trial of its Lymphoseek radiopharmaceutical.To get access to this article and all of the content on AuntMinnie.com, create a free account or sign-in now.Member Sign In:* MemberID ... [Published Aunt Minnie - Jun 11 2014]

Quotes

Original Article: NEXT ARTICLE More From BioPortfolio on "Navidea Biopharmaceuticals' (NAVB) CEO Michael Goldberg on Investor Briefing on Sentinel Lymph Node Biopsy in Head & Neck Cancers (Transcript)"
...macrophages present in tumor-draining lymphatic tissue," said Frederick Cope, Ph D , Senior vice president and Chief Scientific Officer of Navidea. "Tumor-positive lymph nodes recruit cells called Tumor-Associated Macrophages, or TAM's, which are rich in CD206 receptors. The ability of Lymphoseek to specifically target and accumulate in macrophages demonstrated in this study led to localization of the product in tumor-draining pathology-positive lymph nodes that was 18 times higher than in all disease-negative lymph nodes. In the clinic, this reliable uptake of Lymphoseek into appropriate tissue allows for accurate removal and assessment of lymph nodes at highest risk of harboring occult metastases."
"When there's an effective treatment, imaging will become critical to the assessment of an individual," Hartley told DOTmed News. "It's just because we don't have treatments we can't see the benefit of these particular diagnostic tools. I think all of these, once we find some treatments, will show the benefit of these non-invasive tools."
...for patients with oral, head, and neck cancers," said Nancy Leupold, Founder & President of Support for People with Oral, Head and Neck Cancer. "According to the National Cancer Institute, oral, head, and neck cancers account for approximately three percent of all malignancies in the United States, however, post-procedural side effects are more severe than with many other types of cancer. Significant changes in a patient's facial and neck appearance may be present. In addition, a patient may have difficulty with chewing, swallowing, smelling, tasting, speaking and hearing in addition to dental problems."

More Content

All (177) | News (79) | Reports (0) | Blogs (94) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
Navidea Biopharmaceuticals' (NAVB) CEO Michael ... [Published BioPortfolio - Jul 09 2014]
Navidea Webcasting Briefing on Sentinel Lymph N... [Published Individual.com - Jul 08 2014]
Thoratec Acquires Irish Implant Systems Maker [Published Yahoo! Finance - Jul 03 2014]
Navidea to Webcast Investor Briefing on Sentine... [Published EON Science - Jul 02 2014]
Navidea to Webcast Investor Briefing on Sentine... [Published Business Wire Science: Science News - Jul 02 2014]
Navidea to Webcast Investor Briefing on Sentine... [Published Business Wire Health News - Jul 02 2014]
ABIOMED Acquires Germany's Medical Device Maker [Published Yahoo! Finance - Jul 02 2014]
Navidea announces positive results from Phase I... [Published Individual.com - Jun 27 2014]
Navidea announces encouraging data from Phase I... [Published PredictWallStreet - Jun 27 2014]
Platinum Management Buys More Echo Therapeutics... [Published InsiderMonkey.com - Jun 25 2014]
FDA grants expanded use for Lymphoseek [Published Dermatology Times - Jun 25 2014]
Amyloid PET imaging development continues despi... [Published FierceMedicalImaging - Jun 23 2014]
Navidea Gets U.S. FDA Approval for sNDA for Exp... [Published Individual.com - Jun 19 2014]
Lymphoseek: Newly approved for oral cavity canc... [Published MolecularImaging.net - Jun 18 2014]
Navidea bags expanded FDA nod for Lymphoseek [Published Fierce Drug Delivery - Jun 18 2014]
Navidea Biopharmaceuticals to Present at the 9t... [Published Finwin - Jun 17 2014]
Navidea Biopharmaceuticals to Present at the 9t... [Published BioPortfolio - Jun 17 2014]
Navidea Biopharmaceuticals to Present at the 9t... [Published Business Wire Health News - Jun 17 2014]
Navidea's sNDA for Lymphoseek injection gets FD... [Published Pharmaceutical Technology - Jun 17 2014]
U.S. FDA Approves Navidea Biopharmaceuticals' L... [Published Dotmed - Jun 16 2014]
NAVIDEA BIOPHARMACEUTICALS : Regulation FD Disc... [Published 4 Traders - Jun 16 2014]
FDA approves Navidea's Lymphoseek for expanded ... [Published BioPortfolio - Jun 16 2014]
Medical News Today: FDA approve Lymphoseek to e... [Published Medical News Today - Jun 16 2014]
FDA approves Navidea's Lymphoseek for expanded ... [Published PBR - News - Jun 16 2014]
Anheuser Busch, MillerCoors Secrets Unveiled --... [Published The Street Latest - Jun 15 2014]
This Week in Biotech: Actions Speak Louder Than... [Published Motley Fool Discussion Boards - Jun 14 2014]
FDA Approves New Indication For Navidea's Lymph... [Published RTTNews.com - Jun 14 2014]
FDA approves new Lymphoseek indication [Published Aunt Minnie - Jun 13 2014]
FDA Approves Lymphoseek to Help Determine Exten... [Published PT Community - Jun 13 2014]
FDA Approves Lymphoseek to Help Determine Exten... [Published Oncology Times - Jun 13 2014]
1 2 3 4 5 6
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Navidea to Webcast Investor Briefing on Sentine... [Published EON Science - Jul 02 2014]
DUBLIN, Ohio--(EON: Enhanced Online News)--Navidea will host a webcast of an investor briefing to discuss the role of sentinel lymph node biopsy in head and neck cancers on Tuesday, July 8, 2014 with a guest speaker, Dr. Stephen Lai. ...
Navidea to Webcast Investor Briefing on Sentine... [Published Business Wire Science: Science News - Jul 02 2014]
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea will host a webcast of an investor briefing to discuss the role of sentinel lymph node biopsy in head and neck cancers on Tuesday, July 8, 2014 with a guest speaker, Dr. Stephen Lai. ...
Navidea to Webcast Investor Briefing on Sentine... [Published Business Wire Health News - Jul 02 2014]
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea will host a webcast of an investor briefing to discuss the role of sentinel lymph node biopsy in head and neck cancers on Tuesday, July 8, 2014 with a guest speaker, Dr. Stephen Lai. ...
Navidea Biopharmaceuticals to Present at the 9t... [Published Business Wire Health News - Jun 17 2014]
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea to present at JMP Securities Healthcare Conference on June 24, 2014 at 2 p.m. EDT. ...
FDA approves Navidea's Lymphoseek for expanded ... [Published PBR - News - Jun 16 2014]
The US Food and Drug Administration (FDA) has approved Navidea Biopharmaceuticals' Supplemental New Drug Application (sNDA) for the expanded use of Lymphoseek (technetium Tc 99m tilmanocept) Injection indicated for guiding sentinel lymph node (SLN) biopsy ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Navidea Announces Restructuring of Pipeline Dev... [Published GlobeNewswire: Advertising News - May 15 2014]
Technical Data on Biotech Equities -- Research ... [Published Financial Services - May 14 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.